NFKB1 and bladder transitional cell carcinoma: Although there is currently no LUBAC inhibitor available for effective in vivo use, we have demonstrated in our in vitro experiments that the LUBAC inhibitor HOIPIN-8 can significantly suppress NF-κB activation induced by PI16 and the motility and invasion of BLCA cells.